Featured Research

from universities, journals, and other organizations

Promising treatment for aggressive lymphoma identified in new study

Date:
May 27, 2010
Source:
Mayo Clinic
Summary:
New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

Related Articles


The international study, involving 24 medical centers in the United States and Europe, will be presented at the American Society of Clinical Oncology annual meeting June 4-8, 2010, in Chicago.

Forty-five percent of patients with transformed lymphoma treated with lenalidomide responded positively to this immunomodulatory medication, which kills lymphoma cells by activating the body's natural killer cells and by interrupting cancer cell signaling that leads to cell death. Of those patients, 21 percent showed complete remission, some for more than a year.

Transformed lymphoma is an aggressive form of blood cancer. With current therapies, patients have a median survival rate of 1.7 years. In comparison, patients with indolent or slow-growing lymphoma can live 10 to 20 years with the disease. However, over the course of a decade, about 30 percent of those with indolent lymphoma develop transformed lymphoma.

"The study results show a remarkable response rate for transformed lymphoma patients who have a very poor prognosis," says Craig Reeder, M.D., Mayo Clinic hematologist and principal investigator for the phase II study at Mayo Clinic's Arizona campus. Phase II studies typically include no more than 300 patients and are designed to evaluate the effectiveness of a specific therapy.

The study included 217 patients with aggressive lymphoma. Of those, 33 had transformed lymphoma and were treated with lenalidomide. These patients ranged in age from 42 to 84. More than half had stage IV disease, where the lymphoma has spread to multiple sites or organs. All patients had been treated with chemotherapy and some with stem cell transplant to curtail the cancer. The median number of previous treatments was four and ranged up to 12.

Patients took lenalidomide pills (25 mg) daily for 21 days. For seven days, no medication was given. The medication continued until signs of cancer progression. Overall, 45 percent of patients responded positively to the therapy, but results varied by the particular type of transformed lymphoma.

For transformed follicular lymphoma, the most common form of the illness, 13 of the 23 patients (57 percent) in this subgroup responded positively to lenalidomide. Ten patients with other types of transformed lymphoma did not respond. They included transformed chronic lymphocytic leukemia, small lymphocytic lymphoma and others.

Dr. Reeder notes that while the number of patients treated with lenalidomide was small, the results are promising because of the response rate, the length of the response, and the simplicity of treatment. In patients who responded, the positive effect of lenalidomide was seen for a median of nearly 13 months. Compared to chemotherapy drugs, lenalidomide is easy to administer and is well tolerated. "Its appeal is that it's not toxic to the patient," he says. Side effects were considered mild and included low white blood cell counts.

Lenalidomide is approved by the U.S. Food and Drug Administration to treat multiple myeloma and certain types of myelodysplastic syndrome. Mayo Clinic researchers and others have been studying its potential as a lymphoma treatment for about two years. Further studies are needed to confirm its role in treating patients with transformed lymphoma.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Promising treatment for aggressive lymphoma identified in new study." ScienceDaily. ScienceDaily, 27 May 2010. <www.sciencedaily.com/releases/2010/05/100526151531.htm>.
Mayo Clinic. (2010, May 27). Promising treatment for aggressive lymphoma identified in new study. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2010/05/100526151531.htm
Mayo Clinic. "Promising treatment for aggressive lymphoma identified in new study." ScienceDaily. www.sciencedaily.com/releases/2010/05/100526151531.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins